Akero Therapeutics (NASDAQ:AKRO) in a research report issued to clients and investors on Monday, July 15th, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $34.00 price target on the stock. Roth Capital’s price target would indicate a potential upside of 51.92% from the company’s current price.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.